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Abstract
In the present work, the antitumor effect of fastuosain,
a cysteine proteinase from Bromelia fastuosa, was
investigated. In the intravenous model of lung coloni-
zation in C57Bl/6 mice, fastuosain and bromelain in-
jected intraperitoneally were protective, and very few
nodules of B16F10-Nex2 melanoma cells were de-
tected. Tumor cells treated with fastuosain showed
reduced expression of CD44 and decreased invasion
through Matrigel, lost their cytoplasmic extensions
and substrate adherence, and became round and de-
tached, forming strongly bound cell clusters in sus-
pension. Peritoneal cells recruited and activated by
fastuosain treatment (mainly monocytic cells and
lymphocytes) migrated to the lung, where pulmonary
melanoma metastases grew. Adoptive transference
of peritoneal cells recruited by fastuosain had no
protective effect against lung metastases in recipient
mice. Treatment of green fluorescent protein–chimeric
animals with fastuosain did not change the number
of cells that migrated to the lung, compared to PBS-
injected control mice, but the number of positive major
histocompatibility complex class II cells increased
with fastuosain treatment. Murine antibodies against
fastuosain, bromelain, and cathepsins B and L cross-
reacted in ELISA and recognized surface and cy-
toplasmic components expressed on B16F10-Nex2
cells. Anti-fastuosain antibodies were cytotoxic/lytic
to B16F10-Nex2 cells. Antitumor effects of fastuosain
involve mainly the direct effect of the enzyme and
elicitation of protective antibodies.
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Introduction
Endogenous cysteine proteinases that are expressed and
regulated in defined microenvironments, with complemen-
tary and often contradictory responses, functionally depend on
the biological system examined and generally stimulate angio-
genesis and tumor growth. When exogenously administered,
cysteine proteinases may have several pharmacological prop-
erties and, contrariwise, display antitumor activities.
Fastuosain is a novel cysteine proteinase from Bromelia
fastuosa with an estimated molecular mass of 25 kDa. It
has been purified from the ‘‘gravata´’’ fruit from southeastern
Brazil. The fruit is edible, and its juice is popularly used in the
treatment of bronchitis and asthma. It has been functionally
characterized, cloned, and sequenced by Cabral et al. [1]. This
enzyme is similar to bromelain, with a 79.4% sequence homol-
ogy of identical amino acids. It is also partially homologous
to papain (43% identity) and to mammalian cathepsins L and
B (37.8% and 22.8% identities, respectively). The sequence
QGS(Q)CGSCWAF is 100% conserved in fastuosain, papain,
and cathepsins B and L.
Bromelain has antiedematous, anti-inflammatory, anti-
thrombotic, and fibrinolytic activities, as demonstrated in vitro
and in vivo. It is effective after oral administration and, there-
fore, has become a popular phytotherapeutic drug [2]. Pres-
ently, we compared fastuosain and bromelain, focusing on their
antitumor activities. Bromelain showed antimetastatic efficacy
and inhibited platelet aggregation, growth, and invasiveness of
tumor cells [3,4].
Multienzyme mixtures, comprising cysteine proteinases such
as bromelain and papain and also trypsin and chymotrypsin,
have been used mainly because of the safety and efficacy of
oral administration. Most proteins given orally result in tol-
erance, but long-term exposure to bromelain leads to a high
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anti-bromelain antibody response [5]. These antibodies did
not affect the proteolytic activity of bromelain. The protective
effect of papain, alone or together with trypsin and chymo-
trypsin, against murine melanoma has been reported [6,7].
In the present work, we investigated the effect of fastuo-
sain administration on B16F10-Nex2 growth in vitro and
in vivo. Our results show that fastuosain has antitumor
activity and that this property is due to a direct effect of
fastuosain on tumor cells and also to antibodies to fastuosain
that cross-react with cathepsins B and L. These antibodies
promoted direct cell cytotoxicity and lysis mediated by com-
plement. The cellular immune response raised by active and
inactive fastuosain did not effectively contribute to antitumor
protective effect.
Materials and Methods
Proteases
Bromelain (B-4882; Sigma Chemical Co., St. Louis, MO)
was freshly prepared as a 10- to 20-mg/ml stock solution in
PBS. The protease fastuosain was purified as previously
described [1]. Briefly, the juicy pulp of unripe fruits from
B. fastuosa, popularly known as gravata´, was stirred in a
blender containing chilly buffer A (70 mM acetate buffer,
pH 4.0, containing 2 mM EDTA). The extract was filtered
through cheesecloth and plastic sieve, and centrifuged at
5000g for 40 minutes at 4jC. Ion exchange chromatog-
raphy was performed on an SP-Sepharose column (Phar-
macia, Piscataway, NJ) equilibrated previously with buffer A
and eluted with a convex gradient of buffer B (70 mM ace-
tate buffer, pH 4.0, containing 0–2.0 M NaCl). Fractions
containing proteolytic activity were pooled, concentrated,
and filtered by gel chromatography in a Sephadex G-50
column (Pharmacia) using buffer B. A 15% SDS-PAGE
stained with silver nitrate showed a single protein band with
an estimated Mr of 25 kDa.
Animals
Male C57Bl/6 mice, 6 to 8 weeks old (20–25 g), were
obtained from the Center for Development of Experimental
Models, Universidade Federal de Sa˜o Paulo (Sa˜o Paulo,
SP, Brazil). Male C57Bl/6-GFP transgenic mice, 3 weeks old
(20–23 g), were bred and maintained at the Animal Facility of
Gonc¸alo Moniz Research Center/FIOCRUZ. All animals were
kept in isolators in rooms with controlled temperature (22 ±
2jC) and humidity (55 ± 10%), and continuous air renova-
tion. Animals were housed in a 12-hour light/12-hour dark
cycle and were provided autoclaved rodent diet and water
ad libitum. All experiments were carried out in accordance
with prior approval from the local animal ethics committee.
Cells and Cell Culture
The B16F10 murine melanoma cell line was originally ob-
tained from the Ludwig Institute for Cancer Research, Sa˜o
Paulo branch. At the Experimental Oncology Unit (UNONEX),
we isolated several sublines from the original cell line, and the
melanotic subline used in this work, B16F10-Nex2, is char-
acterized by low immunogenicity and moderate virulence. It
forms lethal subcutaneous tumors, but pulmonary nodules
are formed only when injected endovenously. Cells were cul-
tivated in RPMI 1640 medium (pH 7.2; Invitrogen, Carlsbad,
CA) supplemented with 10 mM Hepes, 24 mM sodium bicar-
bonate, 40 mg/ml gentamycin, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 10% fetal calf serum, all from Invitrogen.
Cells were maintained in culture flasks at 37jC in a humidified
atmosphere with 5% CO2, and cell detachment was per-
formed using a PBS–EDTA (1 mM) solution.
MTT Assay for Cell Viability
B16F10-Nex2 tumor cells were seeded at 103 per well
into 96-well plates (Corning Costar Co., New York, NY)
12 hours previously and incubated with serially diluted pro-
teolytic enzymes up to a final volume of 180 ml (in complete
RPMI medium). At different time points, 20 ml of PBS con-
taining 5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Sigma Chemical Co.] was
added to each well. After 4 hours, 50 ml/well of acid SDS
solution (SDS 10%, HCl 0.84%) was added and incubated
overnight for the solubilization of the formazan crystals
generated. Absorbance was read at 570 nm with a micro-
plate reader (MCC/340; Titertek Multiscan, Flow Laboratory,
Rockville, MD).
Flow Cytometry Analysis of Adhesion Molecules on the
B16F10-Nex2 Cell Surface after Enzyme Treatment
B16F10-Nex2 tumor cells (106 cells/well in 24-well plates)
were treated with serially diluted fastuosain or bromelain up
to a final volume of 1 ml of serum-free RPMI medium for
1 hour at 37jC. After enzyme removal by PBS washings,
cells were resuspended in PBS containing 10% BSA, in-
cubated for 10 minutes on ice, and washed with PBS. After
the addition of 1 mg of fluorescein isothiocyanate (FITC)–
conjugated antibodies against mouse adhesion molecules
(CD44 or ICAM-1; BD Biosciences, San Jose, CA) diluted
in 50 ml of fluorescence-activated cell sorting (FACS) buffer
(PBS containing 1% BSA), cells were incubated on ice pro-
tected from light for 1 hour, washed thrice with PBS, and
resuspended in 2% cold paraformaldehyde (wt/vol). Fluores-
cence was measured on a FACScan flow cytometer (BD
Biosciences), and data were analyzed by CellQuest software
(Becton Dickinson, San Jose, CA). For analysis of adhesion
molecule reexpression on tumor cell surface after enzyme
treatment, B16F10-Nex2 cells were treated with fastuosain,
washed with serum-free RPMI, plated on a six-well plate
(Corning Costar Co.), and incubated in complete RPMI
medium at 37jC and 5% CO2 for different time periods. Cells
were then harvested, and 106 cells were labeled with anti-
CD44 or anti– ICAM-1 as described.
Matrigel Invasion Assay
The effect of protease treatment on B16F10-Nex2 cell in-
vasion was observed in Transwell chambers (3-mm pore size,
12-mm polycarbonate filters; Corning Costar Co.) coated with
Matrigel (Basement Membrane Matrix; Becton Dickinson).
Diluted cold Matrigel (50 mg, or 56 ml of a stock solution
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previously diluted 1:3, vol/vol, in serum-free RPMI) was added
to the upper 24-well Transwell chamber and incubated for
30 minutes at 37jC for gel formation. Lower chambers were
filled with 200 ml of a 10-mg/ml laminin-1 solution, diluted in
serum-free RPMI medium, as a haptotactic substrate. Tumor
cells (2  105 ml1) were treated with fastuosain, bromelain
(10 and 5 mg/ml), or 1 mg of anti-CD44 monoclonal antibody
(mAb; BDBiosciences) in serum-free RPMImedium for 1 hour
at 37jC and 5% CO2. After incubation, cells were washed
and resuspended in 200 ml of serum-free RPMI, added to
the upper Transwell compartment containing polymerized
Matrigel, and incubated for 5 hours at 37jC and 5% CO2.
Cells unable to invade the Matrigel were scraped off me-
chanically from the upper chamber with a cotton swab. After
PBS washings, cells underneath the membrane filter were
fixed in paraformaldehyde (3.7%) for 15 minutes and stained
with 0.1% toluidine blue solution for 2 minutes at 37jC; after
washing with tap water, the filters were incubated with
200 ml of 1% SDS solution for 1 hour at 37jC. This solution
was transferred to a 96-well ELISA plate, and absorbance
was measured at 600 nm in a microplate reader (MCC/340;
Titertek Multiscan).
Obtention of C57Bl/6-GFP–Chimeric Mice
C57Bl/6 mice were lethally irradiated with 600 rad. Adult
male hemizygous green fluorescent protein (GFP) donor
transgenic mice were killed by cervical dislocation under
deep anesthesia, and bone marrow was obtained by flush-
ing the femur and tibia with serum-free RPMI medium. Cells
were washed, counted, and resuspended in sterile saline at
a concentration of 108 cells/ml. Two hundred microliters of
the suspension was administrated intravenously into each
irradiated C57Bl/6 recipient animal. Chimeric mice were al-
lowed to recover from manipulation and to have their mar-
row engrafted for 1 month before an intravenous injection
of B16F10-Nex2 cells. For control, flow cytometry was per-
formed with some animals to check the presence of GFP
cells in chimeric bone marrow.
Experimental Tumor Metastasis Assay In Vivo
C57Bl/6 wild-type or GFP-chimeric mice were injected
intravenously into lateral tail veins with 100 ml of PBS con-
taining 5  105 B16F10-Nex2 viable cells. Intraperitoneal
injections of fastuosain (60 mg/animal) or PBS (control group)
were started on the same day and repeated three times a
week for 21 days. After the administration of anesthesia,
the animals were killed by cervical dislocation, their lungs
were collected and formalin-fixed, and pulmonary nodules
were counted with the aid of an inverted microscope.
Following the counting of nodules, lungs were dehydrated
and embedded in paraffin by routine methods for immuno-
histopathological analysis. Paraffin sections of GFP-chimeric
animals (5 mm) were stained with anti-GFP antibodies con-
jugated with Alexa-Fluor 488 (Molecular Probes, Carlsbad,
CA). For quantification of major histocompatibility complex
(MHC) class II–expressing cells, lung sections were stained
using a biotin-conjugated mAb (BD Biosciences), followed
by incubation with streptavidin conjugated with Alexa 568
(Molecular Probes). Nuclei were stained with 4V,6-diamidino-
2-phenylindole dihydrochloride (DAPI; VectaShield Hard Set
mounting medium with DAPI H-1500; Vector Laboratories,
Burlingame, CA). Fluorescent cells were observed in a BX61
microscope with an epifluorescence system plus grid to
enhance fluorescence resolution (OptiGrid Structured Light
Imaging System; Thales Optem, Inc., Fairport, NY) using
appropriate filters (Olympus, Tokyo, Japan). Images were
captured using a color digital video SPOT flex camera (15.2,
64 Mp, Shifting Pixel; Diagnostic Instruments, Inc., Sterling
Heights, MI).
Flow Cytometry of Total Peritoneal Cells and Macrophages
Isolated from Fastuosain-Treated Animals
Twenty male C57Bl/6 mice were intraperitoneally treated
with fastuosain or with fastuosain treated with E-64, a cys-
teine protease inhibitor, to inhibit enzyme catalytic activity.
The treatment consisted of 60-mg injections of active or in-
activated enzyme three times a week for 21 days. Peritoneal
cells were then collected with cold serum-free RPMI, and part
of these cells were submitted to 3-hour adhesion on a Petri
dish for obtention of a macrophage-enriched fraction. Non-
adherent cells were removed by serum-free medium wash-
ings. To detach macrophages from the plates, they were
placed on ice for 15 minutes, followed by cold PBS washings.
After counting, total peritoneal and macrophage-enriched
cells were incubated with FITC-conjugated, phycoerythrin-
conjugated, or unlabeled mAbs for 1 hour on ice. When an
unlabeled antibody was used, this step was followed by a
second incubation with an anti-mouse Ig conjugated with
a fluorochrome (FITC or phycoerythrin) for 30 minutes. All
samples were fixed with 0.4% paraformaldehyde before
analysis on a FACScan Flow cytometer (BD Biosciences).
F4/80 expression was used to gate macrophage cells. The
mAbs used were antibodies to CD11b (Mac-1), CD1d, CD3e,
CD54 (ICAM-1), CD119 [interferon (IFN) g receptor], CD11c,
CD25, CD4, CD80 (B7), CD86 (B7.2), CD90 (Thy-1), CD178
(Fas-L), MHC I, MHC II, NK 1.1, CD8a, CD44, and Vb8.2
TCR (BD Biosciences).
Production of Polyclonal Monospecific Murine Antibodies
against Fastuosain, Papain, and Bromelain: Purification
of Protease-Specific IgG and Detection By ELISA
Male Balb/c mice, 6 to 8 weeks old, were treated in-
traperitoneally with four doses of 250 mg/100 ml fastuosain,
bromelain, or papain, or with the same volume of PBS (control
animals) once a week. One week after the last injection,
serum was collected, and antibodies were precipitated by
saturated ammonium sulfate solution. To purify specific pro-
tease antibodies, tresyl-agarose resin (Supelco, Bellefonte,
PA) was coupled with fastuosain or bromelain, and purified
antibodies were affinity-chromatographed. IgG protease–
specific fraction was isolated using a Protein G column
(Hi-Trap Protein G affinity column; Amersham Biosciences,
Piscataway, NJ). Silver-stained 12% SDS-PAGE was per-
formed to verify the purity of antibody preparation.
The binding specificity of purified antibodies was veri-
fied by ELISA. Proteases (100 pg/100 ml) were added on
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96-well plates (ELISA Hi Binding Plate; Nunc, Roskilde,
Denmark) and incubated overnight at 4jC in 50 mM
carbonate–bicarbonate buffer (pH 9.6). Unbound antigen
was removed by washings with PBS containing 0.05%
Tween 20 (PBS-T). After blocking for 5 hours with PBS
containing 5% fat-free powder milk and 2% BSA, plates were
washed with PBS-T; anti-fastuosain, anti-papain, and anti-
bromelain purified antibodies, or commercial anti–cathepsin
B antibodies (Calbiochem, Darmstadt, Germany) serially di-
luted in reaction buffer (PBS containing 2% fat-free powder
milk and 1% BSA) were added. After overnight incubation at
4jC, plates were washed with PBS-T, and HRP-conjugated
anti-mouse antibody (ICN Biomedicals, Inc., Irvine, CA) was
added (diluted 1:1000 in reaction buffer). After 5 hours of
incubation at 4jC, the reaction was revealed with a spe-
cific substrate (orthophenylenediamine) and stopped with
4 N H2SO4. Absorbance was read at 490 nm with a micro-
plate reader (MCC/340; Titertek Multiscan).
Determination of the Reactivity of Antiproteases with
B16F10-Nex2 Cells By Flow Cytometry
The reactivity of anti-fastuosain, anti-bromelain, anti–
cathepsin B, and anti–cathepsin D antibodies with B16F10-
Nex2 melanoma cells was verified by flow cytometry.
B16F10-Nex2 cells (106) were permeabilized or not with
PBS containing 0.05% saponin. The cells were then incu-
bated for 1 hour on ice with 1 mg of purified polyclonal IgG
against proteolytic enzymes; or with commercial mAbs anti-
CD44 (BD Biosciences), anti–cathepsin B, or anti–cathepsin
D (Calbiochem); or yet with an irrelevant mAb anti– IL-5
(BD Biosciences). Polyclonal antibodies and mAbs were
diluted in 50 ml of FACS buffer (PBS containing 1% BSA and
1% normal mouse serum). After washings with PBS, cells
were incubated for 1 hour with FITC-conjugated secondary
antibodies and resuspended in 2% cold paraformaldehyde
(wt/vol). Analyses were performed on a FACScan flow cytom-
eter (BD Biosciences). As negative control, FITC-conjugated
secondary antibodies were used without primary antibody
binding. Data were analyzed with CellQuest software.
Confocal Microscopy with Anti-Fastuosain
Purified Antibodies
B16F10-Nex2 cells were seeded on sterilized round
coverslips (Fisher Scientific Co., Pittsburgh, PA) inserted
into 24-well plates and allowed to reach 80% confluency.
Cells were then fixed with cold paraformaldehyde (3.7%) and
permeabilized with PBS containing 0.5% saponin. Cover-
slips were washed with saponin buffer (PBS containing
0.05% saponin and 1% BSA); incubated with purified anti-
fastuosain, anti–cathepsin B, and anti– IL-5 antibodies di-
luted in this buffer for 1 hour on ice; and washed twice with
saponin buffer. FITC-conjugated anti–mouse Ig antibody
(BD Biosciences) and phalloidin (Molecular Probes), diluted
in saponin buffer, were incubated for 1 hour on ice. Slides
were washed in PBS and distilled water, and mounted
using Vectashield (Vector Laboratories) in the presence of
10 mg/ml DAPI. They were examined with laser-scanning
fluorescence confocal microscopy (Bio-Rad MRC 1024/UV
System; Bio-Rad, Hercules, CA) equipped with a trans-
mitted light detector for Nomarski differential interference
contrast. Images were collected with a 40 1.2/water im-
mersion PlanApo objective (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY), Kalman averaging at least 20 frames
using a 2-mm iris (pinhole) [8]. As negative control, FITC-
conjugated secondary antibody was used without primary
antibody binding.
Adoptive Transfer of Total Peritoneal Cells from
C57Bl/6-GFP Transgenic Mice Treated with Fastuosain
to B16F10-Nex2–Inoculated C57Bl/6 Mice
C57Bl/6-GFP transgenic mice were treated intraperito-
neally with 60 mg/100 ml fastuosain or with the same volume
of PBS (control group) three times a week for 21 days. After
treatment, total peritoneal cells were collected with 5 ml of
cold PBS and centrifuged for 5 minutes at 1500 rpm. The
cell pellet of one mouse was suspended in 0.5 ml of PBS
and inoculated intraperitoneally in one C57Bl/6 mouse (total
peritoneal cells of a mouse transferred to a new mouse).
On the same day, 5  105 B16F10-Nex2 cells (in 100 ml of
PBS) were injected intravenously into the lateral tail veins.
After 21 days, the animals were sacrificed, and their lungs
were formalin-fixed. After counting pulmonary nodules with
the aid of an inverted microscope, the lungs were dehy-
drated and embedded in paraffin by routine methods. Par-
affin sections of 5 mm were stained with anti-GFP antibodies
conjugated with Alexa-Fluor 488 (Molecular Probes) and
analyzed as described for chimeric animals.
Results
While describing the effects of fastuosain on melanoma
cells, some experiments included bromelain because the
two enzymes share amino acid identities as high as 79.4%.
Both enzymes were tested in vitro and in vivo.
Effect of Cysteine Proteinases on Tumor Cell Metastasis
Using the Intravenous Route
Intravenous injection of B16F10-Nex2 melanoma cells in
C57Bl/6 mice is followed by significant lung colonization after
21 days. Intraperitoneal treatment with fastuosain or bro-
melain (60 mg/ml) starting on the same day of intravenous
challenge with tumor cells greatly reduced the number of
lung metastatic nodules (Figure 1). Furthermore, no meta-
static tumor nodules were found in the myocardium, brain,
kidney, liver, and spleen. Apparently, a number of injections
are needed to keep an optimal level of fastuosain in the
circulation to achieve antitumor protective effect.
Effect on Tumor Cell Growth In Vitro
Tumor cell growth was evaluated in vitro in a time-
dependent manner. The cell viability of fastuosain-treated
B16F10-Nex2 was measured by MTT assay. After 72 hours
of treatment, the inhibitory effect of fastuosain (2.5–10 mg/ml)
was significant, as shown in Figure 2A. B16F10-Nex2 mela-
noma cells were also quite sensitive to bromelain treatment
(Figure 2B). After 96 hours of treatment with fastuosain and
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bromelain, the growth of B16F10-Nex2 melanoma cells was
completely inhibited. By examining cell morphology, it was
observed that fastuosain—more than bromelain—caused
cell detachment and formation of clusters and aggregates
that still contained live cells within (Figure 2, C and D). These
cells were not stained by trypan blue and could return to
normal morphology after removal of the enzyme (data not
shown). The enzyme seemed to affect intercellular and sub-
strate adhesion, with no direct killing of tumor cells.
CD44 Expression
Fastuosain could influence the expression of surface
molecules on B16F10-Nex2 cells, and the first component
examined was CD44, owing to its role in tumor cell adher-
ence. The expression of CD44 on B16F10 melanoma cells
has also been described as a target of bromelain [9]. After
treatment with fastuosain at 5 mg/ml, no CD44 expression
was detected on the cell surface (Figure 3A). Removal of
CD44 was dose-dependent and was not observed when
fastuosain had its catalytic activity abolished by E-64. A
similar response was obtained with bromelain (Figure 3B).
Reexpression of CD44 molecule on the cell surface after
fastuosain removal was also examined. After fastuosain
treatment (10 mg/ml for 1 hour), the enzyme was removed
by washing, and CD44 levels were measured immediately,
after 2 hours, and after 5 hours. Five hours after fastuosain
removal, 40% of the CD44 molecule was reexpressed on
B16F10 Nex2 cells. Reexpression of CD44 was heteroge-
neous, and at least two populations were seen with different
CD44 contents after 5 hours.
Effect of Fastuosain on Tumor Cell Invasion
Tumor cell invasion of connective tissues and basal
membrane is usually tested in vitro using Matrigel, a prod-
uct of a murine sarcoma cell line. The test using Transwell
chambers can measure both migration of cells and penetra-
tion through Matrigel and across a membrane, using laminin
as a haptotactic stimulus. After the fastuosain and bromelain
treatment (10 mg/ml) of B16F10-Nex2 melanoma cells, a
significant reduction in cell invasion through the reconstituted
basal membrane was observed (60% invasion compared to
controls without treatment). Incubation of tumor cells with
mAb anti-CD44 was also effective in reducing the invasion
rate (about 70% invasion), compared to untreated controls
(Figure 4). In a previous test of cell migration in the absence
of Matrigel, treatment with either fastuosain or bromelain did
not change the migration rate, which, therefore, does not
seem to depend on CD44 (data not shown). The same was
observed with the addition of anti-CD44 antibody.
Recruitment and Surface Antigen Expression on Peritoneal
Cells in Mice Injected Intraperitoneally with Fastuosain
The effect of proteolytic enzymes on the cell surface ex-
pression of molecules involved in lymphocyte adhesion and
activation has been reported in vitro [10,11]. Presently, we
investigated the recruitment and expression of surface anti-
gens on peritoneal cells after the intraperitoneal injection of
active fastuosain (60 mg) and fastuosain inactivated by E-64.
The protocol of fastuosain administration was the same as
used before in a lung colonization model. After 21 days, peri-
toneal cells were harvested, washed, and labeled with anti-
bodies to CD119, CD11b, CD11c, CD1d, CD25, CD4, CD8a,
CD54, CD80, CD86, CD3e, CD44, MHC I, MHC II, NK 1.1,
CD90, or CD178 following analysis by flow cytometry (FACS)
(Table 1). Antigen expression as a function of cell recruit-
ment and activation by fastuosain was clearly stimulated for
CD178, CD3, CD86, CD25, and CD11b. Generally, labeling
of peritoneal cells was comparable in both systems of active
and inhibited fastuosain administration, with some excep-
tions, notably CD80, which was less expressed in the active
fastuosain-injected group. We focused next on macrophages
that represent a critical link between innate and adaptive im-
munity and are important modulators of tumor growth.
Total adherent cells were double-stained with anti–F4/80 (a
pan macrophage marker), anti-CD119 (IFN-g-R), anti-CD11b
(Mac-1), anti-CD80, anti-CD86, anti–MHC I, and anti–MHC II
antibodies (Figure 5). Both treatments with fastuosain or
Figure 1. Inhibitory effects of enzyme treatment on pulmonary metastasis in
C57Bl/6 mice intravenously injected with B16F10-Nex2 melanoma cells (1 
105). Fastuosain and bromelain (60 g) were administered intraperitoneally
every other day for 21 days. Mice were killed on day 21 after tumor cell
challenge, and lungs were fixed in formaldehyde (10%). Pulmonary nodules
were counted using an inverted microscope. Photographs of lung metastatic
colonies in the fastuosain group (A), bromelain group (B), and untreated
control group (C) are shown.
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inactive fastuosain promoted a significant increase in the
expression of those antigens, with the exception of CD119,
which was less expressed than in the PBS-treated control
group (Figure 5). This result suggests that the fastuosain
protein (active/inactive) activated macrophages and that
proinflammatory response, including IFN-g production, led to
downregulation of the respective receptor.
Adoptive Transference of Peritoneal Cells from GFP
Animals to Wild-Type C57Bl/6 Mice
This experiment aimed at determining whether total peri-
toneal cells from animals that went through the complete
protocol of fastuosain administration could protect naı¨ve
animals challenged intravenously with B16F10-Nex2 cells.
The fastuosain treatment protocol was therefore reproduced
in GFP animals, and, after 21 days, green peritoneal cells
were transferred to the peritoneum of naı¨ve mice simul-
taneously with intravenous injection of tumor cells. After
21 days of adoptive cell transference and challenge with
tumor cells, a slight reduction in lung metastatic colonies
was observed in relation to the control group that received
peritoneal cells treated with saline (data not shown), but the
difference was not statistically significant. Twenty-one days
after adoptive transference, the number of green peritoneal
cells in the lung was rather reduced but was still detectable
and was similar in the fastuosain and control groups (not
shown). It was evident that peritoneal cells migrated to the
lung, where metastatic nodules developed but, alone, were
not able to protect mice against melanoma growth.
Lung Metastatic Colonization in Fastuosain-Treated
GFP-Chimeric Animals
One month after the irradiation of wild-type C57Bl/6 mice
and the reconstitution of the bone marrow of these animals
with GFP bone marrow cells, chimeric mice were intrave-
nously injected with melanoma cells and treated with fastuo-
sain (intraperitoneally) using the same protocol as above.
After 21 days, chimeric animals were sacrificed and lung
tumor colonies were counted. The result was identical to that
using wild-type C57Bl/6 mouse, with full protection being
obtained on fastuosain treatment (Figure 6A).
Immunofluorescence staining using anti-GFP antibodies
demonstrated intense migration of bone marrow–derived
green cells to the lung parenchyma. No significant alteration
in GFP cell migration was observed in animals treated with
fastuosain compared to the saline-treated group (data not
shown). However, the number of MHC class II–positive cells
in the lung increased after fastuosain treatment (about 43%;
Figure 6B).
Assays Using Anti-Fastuosain Polyclonal Antibodies
In addition to the direct cytotoxic activity of fastuosain on
melanoma cells, induction of anti-fastuosain antibodies could
also play a role in antitumor protection. Furthermore, con-
sidering the sequence similarities of cysteine proteinases,
particularly between fastuosain and bromelain (79.4% iden-
tity), the cross-reactivity of antibodies to these enzymes was
also examined.
Anti-fastuosain antibodies were able to recognize bro-
melain with 100% binding in comparison to the homologous
Figure 2. Direct effect of enzyme treatment on B16F10-Nex2 cells. Cells were plated at 1  103 into 96-well plates in quadruplicates and treated with increas-
ing concentrations of fastuosain (A) and bromelain (B). The growth of melanoma cells was measured at various time periods using the MTT method: (n) 10 g/ml;
(x) 5 g/ml; (E) 2.5 g/ml; (5) control cells. Alterations in cell morphology were observed after 48 hours of fastuosain (C) and bromelain (D) treatment (10 g/ml).
(E) Untreated tumor cells. Scale bars, 20 m.
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recognition of fastuosain (Figure 7A). Cross-reactivity with
the animal cysteine proteinases cathepsins B and L was
observed with 56% and 49% binding, respectively. In agree-
ment with shared epitopes, anti–cathepsin B antibodies
recognized cathepsin L (70% binding) and also reacted with
fastuosain and bromelain (48% and 23% binding, respec-
tively; Figure 7B).
Aiming to verify whether anti-fastuosain antibodies were
able to recognize antigens expressed on B16F10-Nex2
melanoma cells, we performed a flow cytometry analysis
using B16F10-Nex2 cells permeabilized and nonpermeabil-
ized with saponin. With nonpermeabilized cells, fastuosain
antibodies recognized surface components, with 30% bind-
ing taking the reactivity of anti-CD44 antibodies with mela-
noma cells as 100%. Anti-bromelain antibodies bound with
17% intensity (Figure 8). We also observed a high binding of
anti–cathepsin B antibody on the tumor cell surface, con-
firming that this enzyme is expressed on the cell surface as
reported by Sloane et al. [12]. After tumor cell permeabiliza-
tion, a great increase in antibody binding, including anti-
fastuosain, anti-bromelain, and anti–cathepsin B antibodies,
was observed (Figure 8). Confocal microscopy of saponin-
permeabilized cells showed intense anti-fastuosain antibody
reactivity that was concentrated in certain areas but also
spread to the cytoplasm. Labeling with anti–cathepsin B was
more discrete in some defined regions (Figure 9).
Antitumor Activity of Anti-Fastuosain Antibodies
Because anti-fastuosain antibodies reacted with the sur-
face and cytoplasmic components of B16F10-Nex2 cells
and also cross-reacted with cathepsins B and L, we deter-
mined the direct cytotoxicity of these antibodies on melano-
ma cells with and without complement. Anti-fastuosain
antibodies reduced by half the viability of tumor cells simi-
larly with the activity of complement (1:80). The association
of anti-fastuosain antibodies and complement further in-
creased cytotoxicity, with reduction of cell viability to 30%
(Figure 10).
Discussion
Exogenously added proteinases may protect against tumor
growth, in contrast with endogenous proteinases that, in many
cases, have been associated with cancer development. In-
creased expression of cathepsin B, for instance, correlates
with tumor progression and metastatic potential [12–14].
Figure 3. Effect of fastuosain (A and C) and bromelain (B) treatment (1 hour) of B16F10-Nex2 cells on CD44 expression. Open peaks represent CD44 expression
on untreated tumor cells; solid curves show CD44 expression after enzyme treatment at indicated concentrations. E-64 is a specific inhibitor of cysteine pro-
teinases. The time course of CD44 reexpression on fastuosain-treated B16F10-Nex2 cells (10 g/ml for 1 hour) after fastuosain removal is shown in (C). Data
shown are representative of four independent experiments.
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Increased cathepsin L in primary melanoma suggests early
metastatic property [15]. The use of cysteine proteinase
inhibitors reduced the invasibility of B16 murine melanoma
in vitro [16], and deficiency in cathepsins B, L, and S reduced
the tumor growth of pancreatic RT2 cells and affected angio-
genesis [17].
In contrast, administration of proteolytic enzymes (tryp-
sin, chymotrypsin, and papain) using different protocols was
highly effective against subcutaneously growing Lewis lung
carcinoma cells in C57Bl/6 mice [18]. In the syngeneic B16
melanoma model, proteolytic enzymes (a mixture of trypsin,
chymotrypsin, and papain) inhibited the growth of primary tu-
mors, and metastasis was curtailed. This effect was associ-
ated with a decreased expression of CD44 and CD54 in tumor
cells [19]. Much attention has been given to cysteine protein-
ases, particularly to bromelain from Ananas comosus, which
has anti-inflammatory, antithrombotic, and antifibrinolytic prop-
erties. Because bromelain inhibits platelet aggregation, it
affects embolization and, thus, has antimetastatic activity,
but it also reduced the expression of CD44 inMolt4/8 leukemia
and SK-Mel28 human melanoma cells [20].
Fastuosain, a cysteine proteinase, is much related to bro-
melain, sharing 79.4% identical amino acids. Bromelain has
been reported to suppress the growth, invasion, and lung
metastasis of B16F10 murine melanoma cells [9]. The mech-
anisms involved in this protection are poorly understood.
Presently, we investigated the antitumor activity of fastuosain
in comparison with bromelain and determined the basis of
protective effect using the lung colonization model of murine
melanoma B16F10-Nex2 and the intraperitoneal administra-
tion of the enzyme in its active and inactive forms.
Fastuosain, in a protocol of intraperitoneal injections along
with the tumor cell challenge in C57Bl/6 mice, largely inhibited
lung colonization, and this effect matched that of bromelain.
A direct effect of both enzymes on tumor cells was suggested.
Although they inhibited the growth of B16F10-Nex2 cells in
the same concentration range, fastuosain seemed more ac-
tive in detaching cultured tumor cells in vitro, which formed
clusters of viable cells in suspension. Fastuosain also re-
duced the expression of CD44 on tumor cells at concentra-
tions four-fold higher than that of bromelain, and melanoma
cells formed two subpopulations with different levels of re-
expression of CD44 after removal of the enzyme. One of them
almost achieved the same expression of this adhesive mole-
cule as in original tumor cells after 5 hours of incubation. Al-
though CD44 is an important component of tumor cells in
their matrix-invasive capacity, it is clear from the Matrigel in-
vasion experiment that its complete removal from the cell
surface or blocking by anti-CD44 antibody inhibited only up
Figure 4. Effect of fastuosain and bromelain treatment on B16F10-Nex2 cell
invasion of Matrigel in vitro. Treatment with fastuosain or bromelain (10 g/ml,
1 hour) inhibited B16F10-Nex2 cell invasion. Incubation with anti-CD44 mAbs
promotes a similar inhibition of the cell invasion process. The effect is ex-
pressed as percentages relative to controls (invasion by cells treated with
saline). Standard deviations from the means of three experiments are shown.
Figure 5. Effect of intraperitoneal fastuosain treatment on the expression of
surface antigens on F4/80+ macrophages. Peritoneal adherent cells from
animals treated with fastuosain in the native form or with abolished catalytic
activity (by E-64) were analyzed by flow cytometry (FACS). Changes in the
mean fluorescence intensity of cells in relation to the control group (injected
with PBS) are shown.
Table 1. Effect of Intraperitoneal Fastuosain Treatment on the Expression of
Cell Surface Antigens, as Analyzed By FACS.
Antigen Fastuosain Inactive Fastuosain
CD178 ++ +++
CD90 + +
CD8 + +
CD4  +
NK 1.1 ++ +
MHC II + +
MHC I ++ +
CD44 ++ +
CD3 ++ +++
CD86 ++++ ++++
CD80  +++
CD54 + +
CD25 ++++ ++++
CD1d  +
CD11c + ++
CD11b ++ ++
CD119  +
Total peritoneal cells from animals treated with fastuosain in its active form
or with inhibited catalytic activity (E-64 treatment) were examined.
Changes in the mean fluorescence intensity of cells, compared to the control
group injected with PBS, are shown as follows: () lower expression; (+) equal
to control; (++) increased expression, 1.5 times the antigen expression in con-
trols; (+++) increased expression, 2 times the antigen expression in controls;
(++++) increased expression, > 2 times the antigen expression in controls.
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to 30% to 40% of cell invasion. Other components are there-
fore important in melanoma cell invasion. Administration of
cysteine proteinases in vivo may, however, reduce CD44
expression in cells of the immune system. Oral bromelain
therapy in breast cancer patients, for instance, although pos-
sessing antitumor activity, reduced the expression of CD44 on
patient lymphocytes [21].
Because the antitumor effect of fastuosain was obtained
by a series of intraperitoneal injections, we investigated the
immune cells recruited and their capacity of migration to the
lungs and eventual antitumor activity. It is interesting to note
that the inactive form of fastuosain recruited a very similar cell
population to the peritoneum compared with the active en-
zyme, with a few exceptions suggested by the different
expression of surface antigens. These cells were mainly
lymphocytes and cells of monocytic lineage. Some of the
main antigens expressed as induced by inactive fastuosain
were CD3, CD80, CD86, CD25, CD11c, CD11b, and CD178.
When F4/80+ macrophages were selected from recruited
cells, besides CD11b, CD80, and CD86, MHC classes I and
II showed also increased expression. Noticeable was the
decreased expression of CD119 (IFN-g-R) in cells recruited
by both active and inactive fastuosain. This could be ex-
plained by the internalization of the receptor after binding to
IFN-g [22], and it is an indication of macrophage activation
in vivo promoted by fastuosain. With bone marrow and
peritoneal resident macrophages, however, fastuosain did
not stimulate nitric oxide production in IFN-g–preactivated
cells (data not shown). In contrast, bromelain increased nitrite
accumulation in RAW 264-7 murine macrophage cells in the
presence of IFN-g, but not lipopolysaccharide alone [23].
Using the adoptive transference of peritoneal cells from
GFP mice treated with fastuosain to wild-type C57Bl/6 mice,
we showed that green cells migrated to the lungs of mice
challenged with melanoma cells but were not able to con-
trol metastatic growth. Using GFP-chimeric mice with green
bone marrow cells, we found that these cells migrated to
the lungs with tumor-growing cells but in equal numbers,
Figure 6. Fastuosain treatment (intraperitoneally, for 21 days) of GFP-chimeric
C57Bl/6 mice injected intravenously with B16F10-Nex2 melanoma cells. GFP-
chimeric mice were treated with fastuosain and challenged intravenously
with B16F10-Nex2 cells (105). (A) Metastatic lung nodules; (B) double-labeled
(GFP+, MHC class II+) cell migration to the lungs of chimeric mice. *P < .05.
Figure 7. Anti-fastuosain (A) and anti –cathepsin B (B) affinity-purified
antibodies cross-react with bromelain and fastuosain and with cathepsins B
and L. Antibody binding was determined by ELISA, taking the homologous
system as 100% reactivity.
Figure 8. Percent flow cytometry analysis of antibody binding to B16F10-
Nex2 cells, permeabilized (black bars) and nonpermeabilized (white bars)
with saponin. Data show the percentages of cells labeled from 104 cells as
examined by FACS.
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when comparing fastuosain-treated and PBS-treated mice.
Fastuosain-treated mice had 40% more MHC class II–
expressing green cells, but their role in antitumor protection
is doubtful. Cross-priming of tumor antigens might, how-
ever, occur, and possible T-CD4+ lymphocyte proliferation
could be a source of IFN-g that is directly cytotoxic to mela-
noma cells [24]. It seems, however, that full protection is
only achieved in the course of fastuosain administration.
This situation is opposite to that of mice with spontaneous
regression/complete resistance, in which resistance is com-
pletely transferable to recipient mice through splenocytes,
bone marrow cells, or enriched peritoneal macrophages [25].
The lack of clear evidence that a cellular immune re-
sponse was the key antitumor mechanism in mice treated
with fastuosain led us to investigate the possibility of an ef-
fective antibody response that could be protective in addi-
tion to direct effects of the cysteine proteinase. Owing to
certain similarities in the sequences of plant and mammalian
cysteine proteinases, antibodies raised against fastuosain
and cathepsin B were shown to cross-react with cathep-
sins B and L, fastuosain, and bromelain. Considering that
B16F10 murine melanoma cells express high levels of ca-
thepsin B [26,27], anti-fastuosain, anti-bromelain, and anti–
cathepsin B antibodies were tested for binding to tumor cells.
Based on anti-CD44 binding to B16F10-Nex2 cells, which
was taken as 100% binding efficiency, anti–cathepsin B
and anti-fastuosain antibodies bound with 70% and 30%
efficiency, respectively. Anti-bromelain antibodies were the
least reactive. Surprisingly, all antibodies were highly reac-
tive with saponin-permeabilized cells. Besides cathepsin B,
other internal targets for antibody reactivity could be cathep-
sins L and S, which have been identified in B16F10-Nex2
cells [28] (T. Paschoalin, unpublished results). Anti-fastuosain
antibodies strongly reacted with the cytoplasm of melanoma
cells, compared to anti–cathepsin B antibodies, which re-
acted on several defined regions of the cell. Fastuosain
used as immunogen for antibody production gave a single
Figure 9. Confocal microscopy of B16F10-Nex2 cells stained with anti –
cathepsin B antibodies (A); anti-fastuosain antibodies (B); and anti – IL-5 anti-
bodies (negative control) (C). Positive reactions labeled with green fluores-
cence. Actin is red-labeled with phalloidin, and nuclei are blue-stained with
DAPI. Scale bars, 20 m.
Figure 10. Anti-fastuosain antibody cytotoxicity on B16F10-Nex2 cells. B16F10-
Nex2 cells were incubated with increasing concentrations of anti-fastuosain
antibodies (1.25–10 g/well) with or without diluted complement (1:80). After
12 hours, cell viability was measured by trypan blue. (A) Control cells with-
out complement and antibody; (B) cells incubated with complement diluted
1:80. Black bars, antibody titration with complement; hatched bars, antibody
at 10 g/well, without complement.
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band in silver-stained SDS-PAGE that is presumably free
of contaminants.
The reactivity of anti-fastuosain antibodies with melanoma
cells, presumably cross-reacting with cathepsin B, is consis-
tent with the association of the latter to tumor cell membrane
[29]. Membrane-associated cathepsin B is important for the
activation of receptor-bound pro–urokinase plasminogen
activator (pro-uPA) that is important for Matrigel invasion
[30]. Caveolin-1 mediates the expression and localization of
cathepsin B, pro-uPA, and their cell surface receptors p11 and
uPAR, respectively [31].
Membrane cathepsin B apparently is a target for anti-
fastuosain antibody binding. Such reactivity reduces by half
the growth of B16F10-Nex2 cells. This cytotoxicity increases
in the presence of complement. We believe, therefore, that
the antitumor activity of fastuosain against melanoma cells
is mainly due to the direct effects of the enzyme on tumor
cells and on proangiogenic endothelial cell extensions, as
shown in vitro (data not shown), but also due to cytotoxic
cross-reactive antibodies raised by fastuosain immuniza-
tion. Cell immunity can have a role (which seems to be a
minor one) in the protection induced by fastuosain in the
lung colonization melanoma model.
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